1st Circ. Crushes Objection To $24M Zoladex Deal
A federal appeals court panel has upheld a $24 million settlement in a class action that accused AstraZeneca Pharmaceuticals LP of artificially inflating prices for the prostate cancer drug Zoladex....To view the full article, register now.
Already a subscriber? Click here to view full article